An Extension of the TG1101‐RMS201 Trial
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 1/12/2019 |
| Start Date: | June 1, 2017 |
| End Date: | September 30, 2019 |
An Open Label Extension of the TG1101‐RMS201 Trial, for Subjects Currently Enrolled in TG1101‐RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal
antibody, in patients with relapsing forms of multiple sclerosis
antibody, in patients with relapsing forms of multiple sclerosis
Inclusion Criteria:
- Subjects currently enrolled in TG1101-RMS201 trial
- Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and
Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled
assessments up to the final 48-week visit
Exclusion Criteria:
- Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101-
RMS201 study during the 48-week evaluation period
- Subjects who have started any other immunomodulating or disease modifying therapy
after completion of the TG1101-RMS201 trial
- Pregnant or nursing mothers
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials